Zhang, T., Harrison, M., O’Donnell, P., Alva, A., Hahn, N., Appleman, L. J., … George, D. J. (2017). Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC). In ANNALS OF ONCOLOGY (Vol. 28). Madrid, SPAIN: OXFORD UNIV PRESS.

Zhang, T., M. Harrison, P. O’Donnell, A. Alva, N. Hahn, L. J. Appleman, J. Cetnar, et al. “Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC).” In ANNALS OF ONCOLOGY, Vol. 28. OXFORD UNIV PRESS, 2017.

Zhang T, Harrison M, O’Donnell P, Alva A, Hahn N, Appleman LJ, et al. Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC). In: ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2017.

Zhang, T., et al. “Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC).” ANNALS OF ONCOLOGY, vol. 28, OXFORD UNIV PRESS, 2017.

Zhang T, Harrison M, O’Donnell P, Alva A, Hahn N, Appleman LJ, Cetnar J, Burke J, Fleming M, Milowsky M, Mortazavi A, Shore N, Schmidt EV, Kresja C, Chen T, Bitman B, Izumi R, Hamdy A, George DJ. Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC). ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2017.